Free Newsletter
Generic Coregs are coming
Free newsletter via e-mail
Tools
The FDA gave its blessing to more than a dozen generic versions of GlaxoSmithKline's Coreg (aka carvedilol), used to treat a variety of cardiovascular problems including high blood pressure and heart failure. Now, Glaxo will have to share the $1.7 billion carvedilol market with the likes of Actavis, Apotex, Caraco, Dr. Reddy's, Ranbaxy, Sandoz, Teva, and Watson, among others. A total of 14 generics were approved.
Ironically, the generic labeling may differ from the brand-name version because, while the drug itself is no longer under patent, certain bits of the labeling are.Â
- see the FDA release
Related Articles:
Riled investors look for big changes at GSK. Report
Patent 'cliff' looms for Big Pharma. Report
More stories about Coreg Ranbaxy Teva Pharmaceutical FDA GlaxoSmithKline Generics FDA approval Patent
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: